Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

2.290 -0.250 (-9.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,794
Open 2.530
Bid (Size) 2.250 (1)
Ask (Size) 2.500 (2)
Prev. Close 2.540
Today's Range 2.250 - 2.600
52wk Range 2.270 - 8.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Silver(II) Antimicrobial Drug Candidate Telomir-Ag2
Via Investor Brand Network
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Via ACCESS Newswire

Performance

YTD
-43.7%
-43.7%
1 Month
-9.8%
-9.8%
3 Month
-41.6%
-41.6%
6 Month
-30.8%
-30.8%
1 Year
-62.1%
-62.1%

More News

Read More
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Data Supporting Expansion into Autism and Rare Neurological Disorders
Via Investor Brand Network
Exposures Product Safety
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success of Telomir-1 in Prostate Cancer Model
Via Investor Brand Network
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Via ACCESS Newswire
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success in Age-Reversal Science with Telomir-1
Via Investor Brand Network
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Stabilizes Silver(II) for Advanced Medical Applications
Via Investor Brand Network
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
Via ACCESS Newswire
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
Via Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results for Age-Related Macular Degeneration
Via Investor Brand Network
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
Via ACCESS Newswire
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Via ACCESS Newswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Findings for Age-Reversal Therapy
Via Investor Brand Network
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Via ACCESSWIRE
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
Via Investor Brand Network
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Via ACCESSWIRE
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
Via Benzinga
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
Via Investor Brand Network
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Via ACCESSWIRE
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
Via Investor Brand Network

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 2.290
When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 05/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.